US20020092524A1 - Medicament respiratory delivery device - Google Patents
Medicament respiratory delivery device Download PDFInfo
- Publication number
- US20020092524A1 US20020092524A1 US09/879,714 US87971401A US2002092524A1 US 20020092524 A1 US20020092524 A1 US 20020092524A1 US 87971401 A US87971401 A US 87971401A US 2002092524 A1 US2002092524 A1 US 2002092524A1
- Authority
- US
- United States
- Prior art keywords
- medicament
- delivery device
- chamber
- cartridge
- passage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 129
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 59
- 239000012528 membrane Substances 0.000 claims abstract description 42
- 239000012530 fluid Substances 0.000 claims abstract description 12
- -1 polyethylene Polymers 0.000 claims description 34
- 239000004698 Polyethylene Substances 0.000 claims description 23
- 229920000573 polyethylene Polymers 0.000 claims description 23
- 229920001169 thermoplastic Polymers 0.000 claims description 11
- 239000004416 thermosoftening plastic Substances 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 7
- 239000010408 film Substances 0.000 description 30
- 229920000098 polyolefin Polymers 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 17
- 239000003085 diluting agent Substances 0.000 description 7
- 239000004743 Polypropylene Substances 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 238000001746 injection moulding Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000004711 α-olefin Substances 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229940122853 Growth hormone antagonist Drugs 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 239000004708 Very-low-density polyethylene Substances 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229920006244 ethylene-ethyl acrylate Polymers 0.000 description 1
- 229920006225 ethylene-methyl acrylate Polymers 0.000 description 1
- 229920005676 ethylene-propylene block copolymer Polymers 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229920000092 linear low density polyethylene Polymers 0.000 description 1
- 239000004707 linear low-density polyethylene Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920001179 medium density polyethylene Polymers 0.000 description 1
- 239000004701 medium-density polyethylene Substances 0.000 description 1
- 239000011104 metalized film Substances 0.000 description 1
- 239000012968 metallocene catalyst Substances 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920005629 polypropylene homopolymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000002644 respiratory therapy Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000007666 vacuum forming Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229920001866 very low density polyethylene Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/06—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump
- B05B11/061—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump characterised by the means producing the gas or vapour pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0033—Details of the piercing or cutting means
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/06—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump
- B05B11/062—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump designed for spraying particulate material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/07—General characteristics of the apparatus having air pumping means
- A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
- A61M2205/073—Syringe, piston type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Definitions
- This invention relates to medicament respiratory delivery devices for pulmonary, intranasal and buccal respiratory delivery of medicaments including an encapsulated medicament cartridge having a piercing element.
- Inhalers and atomizers are now commonly used primarily to deliver various liquid medicaments via the patient's or user's nose or mouth.
- medicament includes any powder or liquid medicament, drug or vaccine which may be administered from a respiratory delivery device through the user's nose or mouth, sometimes referred to herein as a medicament respiratory delivery device.
- unit dose disposable powder medicament delivery devices such as disclosed in U.S. Pat. No.
- the embodiments of the medicament respiratory delivery devices and medicament cartridge of this invention provides a reproducible, high level of clearance of medicament or emitted dose from the cartridge upon actuation with modest gas pressure.
- the medicament respiratory delivery device of this invention includes a housing having a chamber, an inlet communicating with the chamber, and an outlet preferably generally coaxially aligned with the inlet and a medicament cartridge located within the chamber.
- the medicament cartridge includes a body portion having opposed ends and a passage extending through the body portion through the opposed ends.
- the passage is generally cylindrical, but may have other shapes including an hourglass shape.
- the passage includes the medicament, which may be a unit dose of a liquid or powder medicament, drug or vaccine as discussed further hereinbelow.
- a burstable membrane preferably comprising a thin sheet of polyolefin or a polyolefin blend or copolymer having a thickness between 0.3 and 1.5 mils and a burst pressure of between 1.2 and 10 atmospheres, more preferably less than 5 atmospheres and most preferably between 1.5 and 4 atmospheres.
- polyolefin is understood to mean a polymer containing olefin units such as, for example, ethylene, propylene or 1 -butene units or any other alpha-olefin.
- Polyolefin as used herein includes polyethylene, polypropylene, ethylene- .alpha. olefin copolymer, wherein the alpha olefin having from 3 to 20, preferably 4 to 8 carbon atoms, polyolefin copolymers made by polymerizing olefins in the presence of a metallocene catalyst, ethylene-vinyl acetate copolymer, ethylene-ethyl acrylate copolymer, and ethylene-methyl acrylate copolymer.
- polyethylene such as low-density, linear-low-density, very-low-density, medium-density, or high-density polyethylene
- polypropylene such as a polypropylene homopolymer, ethylene-propylene copolymer, or ethylene-propylene block copolymer.
- the end of the cartridge at the outlet of the delivery device is convex or frustoconical surrounding the passage and a polymeric film is stretched taut over the convex surface and bonded or fused to the convex surface, thereby avoiding wrinkles or bulges in the burstable membrane which may adversely affect the consistency of the emitted dose of the delivery device.
- the medicament respiratory delivery device of this invention further includes a piercing element movable to pierce the pierceable closure of the cartridge and a manually compressible pressure actuator which delivers fluid under pressure through the housing inlet upon piercing of the pierceable closure, thereby rupturing the burstable membrane and expressing the medicament in the passage entrained in fluid to the outlet of the delivery device.
- the piercing element pierces the pierceable closure prior to delivery of sufficient pressure to the burstable membrane to rupture the membrane.
- the piercing element includes an actuator portion and a shaft portion having a piercing end and the cartridge includes an integral tubular portion coaxially aligned with the pierceable closure which receives the piercing end of the shaft and which guides the piercing end of the piercing element.
- the actuator portion of the piercing element is located within the pressure actuator, such that actuation of the pressure actuator also moves the shaft portion of the piercing element to pierce the pierceable closure.
- the housing is comprised of two opposed thermoformed thermoplastic sheets bonded together, wherein the sheets have formed therebetween a central chamber, an inlet communicating with the chamber, a collapsible or compressible pressure actuator having an outlet communicating with the inlet to the chamber and an inlet opposite the inlet to the chamber preferably including a generally conical diffuser portion.
- the medicament cartridge is thereby encapsulated between the thermoformed thermoplastic bonded sheets forming the housing chamber.
- the pressure actuator is bulb-shaped, preferably symmetrical with respect to the axis of the inlet and outlet of the chamber; however, the pressure actuator may also be a bellows-type pressure actuator either symmetrical with respect to the axis of the chamber inlet and outlet or extending from either of the thermoformed sheets.
- the acuator portion of the piercing element is bow-shaped having a concave arcuate portion generally conforming to the bulb-shape of the pressure actuator and a concave arcuate portion connected to or integral with the ends of the concave arcuate portion and the shaft portion is connected to the end of the concave portion, such that compression collapsing of the bulb-shaped pressure actuator collapses the actuator portion of the piercing element, driving the piercing end of the shaft through the pierceable closure of the capsule and deliver fluid under pressure to the cartridge passage, rupturing the burstable membrane and expressing entrained medicament through the outlet of the delivery device.
- the medicament respiratory delivery device of this invention may be utilized to aerosolize any medicament, drug or vaccine, referred to herein generically as a medicament, including liquid, powder or even gaseous medicaments.
- the cartridge may contain a unit dose of a liquid or powder medicament or the bulb may be filled with a liquid, such as a diluent or medicament, and the cartridge may be filled with a powder medicament, wherein the powder medicament is simultaneously reconstituted by a diluent, for example, and expressed by the medicament respiratory delivery device of this invention to the respiratory system of a user or patient.
- the preferred embodiments of the medicament respiratory delivery device of this invention are particularly, but not exclusively, adapted for pulmonary, intranasal or buccal medicament delivery of a liquid or powder medicament, wherein the patient's inspiratory flowrate is not the driving force behind the delivery of the medicament.
- the burstable membrane is formed of a preferentially oriented polyolefin film, preferably a uniaxially oriented polyethylene film having a thickness of about 1 mil and having a burst pressure of less than 5 atmospheres.
- Polyolefin films can be oriented by drawing in one or both mutually perpendicular directions in the plane of the film to impart strength thereto using methods known in the art.
- Oriented polyolefin films include machine direction and transverse direction orientation.
- Oriented polyolefin films include uniaxially or biaxially oriented films, with uniaxially oriented films being preferred.
- Uniaxially-oriented films have properties to their advantage for use as the burstable membrane, including relatively high stiffness, as indicated by the tensile modulus in a particular direction, usually the machine direction, compared to the transverse direction. Properties of the oriented polyolefin film can be dependent to a certain degree on the particular process conditions under which the polyolefin film was manufactured. For example, a stiffer film with lower transverse burst pressure properties would result from an orientation process incorporating a larger machine direction orientation draw ratio.
- oriented polyolefins films can be tailored to provide an appropriate burst pressure property within a preferred film thickness range.
- the burstable film may also be formed from various polymers, including cast polyethylene and polyethylene copolymers and scored or embossed polypropylene, acetate or polycarbonate.
- FIG. 1 is a perspective view of a medicament cartridge for the medicament respiratory delivery device of this invention
- FIG. 2 is a top perspective view of a preferred embodiment of the medicament respiratory delivery device of this invention.
- FIG. 3 is a side cross-sectional view of FIG. 2 in the direction of view arrows 3 - 3 ;
- FIG. 4 is a side cross-sectional view of the medicament respiratory delivery device as shown in FIG. 3 during actuation of the device;
- FIG. 5 is a perspective view of the piercing element shown in FIG. 2;
- FIG. 6 is a side cross-sectional view of FIG. 2 wherein the cartridge includes a powder medicament and the bulb includes a liquid diluent;
- FIG. 7 illustrates the medicament respiratory delivery device of FIG. 4 during actuation of the pressure actuator.
- FIG. 1 illustrates a preferred embodiment of the medicament cartridge 20 for the embodiment of the medicament respiratory delivery device 22 illustrated in FIG. 2.
- the cartridge 20 includes a body 24 having opposed ends 26 and 28 and a passage 30 extending through the opposed ends.
- one end 26 serves as the outlet end and the opposed end 28 serves as the inlet end as described further below.
- the outlet end 26 includes a burstable membrane 32 as described above and the inlet end 28 includes a pierceable closure 34 as shown in FIGS. 3 and 4.
- the inlet end 28 further includes a tubular guide 36 for the piercing element as described herein below.
- the body portion further includes a generally V-shaped groove 38 for ease of handling.
- the outlet end 26 of the body 24 is convex or frustoconical surrounding the passage 30 and the burstable membrane 32 comprises a thin polyolefin film which is stretched taut over the convex end 26 and bonded to the convex end, thereby avoiding wrinkles in the burstable membrane 32 which may adversely affect the consistency of the emitted dose from the medicament respiratory delivery device, particularly at lower pressures.
- the burstable membrane 32 is formed from a thin sheet or film of polyolefin or a polyolefin copolymer, most preferably polyethylene or a polyethylene copolymer having a thickness of between 0.3 and 1.5 mils.
- the burstable membrane is formed from a thin preferentially or uniaxially oriented polyethylene film as discussed further below.
- the opposed end of the passage 30 is sealed with a pierceable closure 34 as shown in FIGS. 3 and 4 and a tubular guide 36 is perpendicular to the pierceable closure 34 and coaxial with the passage 30 .
- the pierceable closure 34 may be formed of any suitable material which may be pierced during actuation of the medicament respiratory delivery device.
- the body 24 of the cartridge is formed of the same or a chemically similar polymer as the burstable membrane 32 and the tubular guide 36 and pierceable closure 34 is formed during injection molding of the cartridge body 24 .
- the body 24 , pierceable closure 34 and tubular extension 36 may, for example, be formed of polyolefin polyethylene or a polyolefin copolymer including polyethylene. Included are metallized films of polyolefins.
- the embodiment of the medicament respiratory delivery device shown in FIG. 2 and the following figures may be formed from opposed thermoformed thermoplastic sheets 40 and 42 bonded together by conventional vacuum forming techniques.
- the components of the medicament respiratory delivery device of this invention may comprise separate elements or components utilizing the advantages of the medicament cartridge 20 described hereinbelow.
- the housing formed by the thermoformed thermoplastic sheets 40 and 42 includes an intermediate chamber 44 which encapsulates the cartridge 20 , the housing having an inlet 46 and an outlet 48 which are preferably coaxially aligned with the passage 30 through the cartridge and thus also coaxially aligned with the burstable membrane 32 and pierceable closure 34 as best shown in FIGS. 3 and 4.
- the outlet 48 includes a generally conical diffuser portion 50 integrally formed between the sheets 40 and 42 .
- the configuration of the outlet will depend upon the application of the medicament respiratory delivery device of this invention.
- the disclosed embodiment of the medicament respiratory delivery device 22 of this invention further includes a manually compressible pressure actuator 52 and a piercing element 54 .
- the pressure actuator 52 and the piercing element 54 cooperate to first pierce the pierceable closure 34 of the medicament cartridge and then deliver fluid under pressure through the pierced opening, as shown in FIG. 4, to burst the burstable membrane 32 and express the medicament in the passage 30 through the outlet 48 as described hereinbelow.
- the pressure actuator 52 is bulb-shaped and integrally formed between the sheets 40 and 42 as best shown in FIGS. 2 and 3.
- the bulb-shaped pressure actuator 52 is generally spherical and concentric with the axis 56 of the cylindrical passage 30 through the cartridge.
- the pressure actuator may be a separate collapsible bulb or bellows-type actuator (not shown) or the pressure actuator may extend from either of the sheets 40 or 42 .
- a concentric bulb or spherical actuator is preferred for ease of operation and for use with the piercing element 54 now described.
- the disclosed embodiment of the piercing element 54 includes a bow-shaped actuator portion 58 and a shaft portion 60 having an enlarged sharp piercing end 62 .
- the bow-shaped actuator portion 58 includes a convex portion 64 , which generally conforms to the inside shape of the spherical bulb 52 , and concave portions 66 integral with the ends of the convex portions 64 forming a bow-shape and the shaft 60 is attached to the end of the concave portions 58 , as best shown in FIG. 5.
- the piercing element 54 may be formed from a suitable resilient flexible polymer such as polyethylene, polypropylene, etc. by injection molding.
- the housing of the medicament respiratory delivery device 22 may be vacuum formed from various thermoplastic polymers, including polyethylene, polypropylene, acetate, polycarbonate, etc.
- the sheets 40 and 42 may be separately vacuum formed, the cartridge 20 and the piercing element 54 is then assembled into one of the vacuum formed sheet halves and the vacuum formed sheets may then be heat fused together around the periphery as shown.
- the cartridge 20 may be filled with any suitable medicament, such as the liquid medicament 70 shown in FIG. 3.
- the cartridge may be filled with medicament by injection molding the body 24 and the pierceable closure 34 and integral guide tube 36 . The medicament is then inserted into the cartridge through the open exit end 26 through the passage 30 .
- the burstable membrane 32 is affixed over the frustoconical end 26 of the cartridge by stretching the film and heat bonding or fusing the film to the end 26 of the cartridge.
- the burstable membrane may be adhesively bonded to the end 26 of the cartridge.
- the passage 30 in the cartridge 20 includes a liquid medicament 70 .
- the piercing end 62 of the shaft 60 is received in the tubular guide portion 36 of the cartridge adjacent to the pierceable closure 34 .
- the user compresses the pressure actuator 52 as shown by arrows 72 in FIG. 4.
- the pressure actuator 52 As the pressure actuator 52 is compressed, it engages the convex portion 64 of the actuator portion 58 of the piercing member as shown in FIG. 4, driving the shaft portion 60 to the left in FIG.
- FIGS. 6 and 7 illustrate an alternative use of the medicament respiratory delivery device 22 , wherein the cartridge 20 is filled with a powder medicament 76 and the actuator portion 52 of the housing includes a liquid 78 , such as a diluent or a second medicament.
- a liquid 78 such as a diluent or a second medicament.
- dry medicaments are conventionally reconstituted by adding a liquid, such as a diluent, which is injected into the vial through a syringe.
- the cartridge 20 of this invention is sealed against moisture and thus will maintain a powder medicament for an extended period of time.
- the medicament respiratory delivery device of this invention may thus be used to simultaneously reconstitute and express a powder medicament by storing liquid in the bulb or blister 52 , which is also sealed between the sheets 40 and 42 .
- the operation of the medicament delivery device 22 shown in FIGS. 6 and 7 is essentially identical to the operation of the device as described above in regard to FIGS. 3 and 4. That is, the user compresses the bulb-shaped actuator 52 as shown by arrows 72 , which compresses the convex portion 64 of the piercing element 54 , which drives the piercing end 62 of the shaft portion 60 through the pierceable closure 34 and simultaneously delivers the liquid 78 and gas into the passage 30 of the cartridge and ruptures the burstable membrane 32 .
- liquid 78 is a diluent
- the diluent simultaneously reconstitutes the powder medicament 76 and the reconstituted liquid medicament is then expressed into the diffuser portion 50 of the medicament delivery device as shown arrows 80 to the respiratory system of the user.
- the medicament respiratory delivery device of this invention may be utilized to delivery various substances to the respiratory system of the user including medicaments, drugs and vaccines via the nasal, pulmonary or buccal routes used in the prevention, diagnosis, alleviation, treatment or cure of diseases.
- drugs such as Anti-Angiogenesis agents, Antisense, an to-ulcer, butorphanol, Calcitonin and analogs, COX-II inhibitors, desmopressin and analogs, dihydroergotamie, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Growth hormone and analogs (including growth hormone releasing hormone), Growth hormone antagonists, IgE suppressors, Insulin, insulinotropin and analogs, Ketamine, Kytril, lenizing hormone releasing hormone and analogs, lidocaine, metoclopramide, Midazolam, Narcotic analgesics, neuraminidase inhibitors, nicotine, Non-steroid an to-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Se
- drugs such as Anti-Angio
- Typhoid influenza, hepatitis, including hepatitis A, B, C and E, polio, HIV, parainfluenza, rotavirus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhea, asthma, atheroschlerosis, malaria, otitis media, E-coli, Alzheimers, H.
- the stopper was moved through the barrel under controlled conditions at 25 in/min and the burst pressure (force divided by area) and emitted dose (i.e. percentage of powder emitted from the passage, KPLC assay) was measured.
- the burst pressure force divided by area
- emitted dose i.e. percentage of powder emitted from the passage, KPLC assay
- burstable membrane film was a cast 50/50 polyolefin copolymer of ethylene and methylacrylate and having a thickness of about one mil and a burst pressure of 2 atmospheres, wherein the emitted dose was about 95%.
- the applicant also tested a polyethylene film having a thickness of about 0.9 mil wherein the polyethylene film had a checkerboard embossment having a burst pressure of 3 atmospheres, wherein the emitted dose was about 91%.
- the films formed from other polymers may be utilized for the burstable membrane 32 including, for example, polypropylene, acetate and polycarbonate.
- the pierceable closure 34 may be formed of various pierceable films or sheets.
- the pierceable closure 34 is integrally formed with the body 24 of the cartridge, such as by injection molding.
- the cartridge is most preferably formed from a polyethylene or a polyethylene copolymer, such that the pierceable membrane may also be formed of polyethylene.
- the thermoformed sheets 40 and 42 which form the housing may also be formed from various thermoformable plastic polymers including polyethylene, polypropylene, polycarbonates, etc.
- the passage 30 through the cartridge is preferably generally cylindrical; however, the passage may also include other shapes or configurations including, for example, an hourglass shape.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Mechanical Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Plant Substances (AREA)
- Window Of Vehicle (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
A medicament respiratory delivery device including a housing formed of opposed thermoformed polymeric sheets bonded together having formed therebetween a chamber having a medicament cartridge encapsulated between the sheets, an inlet aligned with a passage through the cartridge having a pierceable closure and an outlet aligned with the passage outlet having a burstable membrane. The device includes a pressure actuator formed as a blister between the sheets and a piercing element having a bow-shaped actuator portion and a shaft which pierces the pierceable closure upon actuation of the pressure actuator, delivering fluid under pressure to the cartridge passage, rupturing the membrane and expressing the medicament.
Description
- This Application is a continuation in part application of Ser. No. 09/758,776 filed Jan. 12, 2001.
- This invention relates to medicament respiratory delivery devices for pulmonary, intranasal and buccal respiratory delivery of medicaments including an encapsulated medicament cartridge having a piercing element.
- Inhalers and atomizers are now commonly used primarily to deliver various liquid medicaments via the patient's or user's nose or mouth. As used herein, “medicament” includes any powder or liquid medicament, drug or vaccine which may be administered from a respiratory delivery device through the user's nose or mouth, sometimes referred to herein as a medicament respiratory delivery device. More recently, the prior art has proposed unit dose disposable powder medicament delivery devices, such as disclosed in U.S. Pat. No. 5,215,221, wherein a predetermined quantity or unit dose of a powder medicament is sealed in a reservoir formed between opposed thermoplastic sheets and expressed or delivered by application of manual force to a thermoformed blister which, upon actuation, breaks a burstable seal between the sheets at the entrance to the reservoir and fluidizes the powder medicament in the reservoir through a delivery tube. The delivery tube is cut prior to use.
- There are several considerations affecting the design and efficacy of medicament respiratory delivery devices. First, it is important to ensure that a predetermined quantity or dose of medicament is consistently delivered to the user with each application. Second, because respiratory therapy often requires numerous applications, the cost of providing the dosage should also be considered. That is, it is desirable that the medicament respiratory delivery device consistently express substantially all of the medicament to the user and that the delivery device is not susceptible to user error in operation. Third, it is important that the medicament be properly disbursed or entrained in the conveying fluid. Further considerations include operating complexity, cost of the device, portability and size of the delivery device.
- The embodiments of the medicament respiratory delivery devices and medicament cartridge of this invention provides a reproducible, high level of clearance of medicament or emitted dose from the cartridge upon actuation with modest gas pressure.
- The medicament respiratory delivery device of this invention includes a housing having a chamber, an inlet communicating with the chamber, and an outlet preferably generally coaxially aligned with the inlet and a medicament cartridge located within the chamber. The medicament cartridge includes a body portion having opposed ends and a passage extending through the body portion through the opposed ends. In the most preferred embodiment, the passage is generally cylindrical, but may have other shapes including an hourglass shape. The passage includes the medicament, which may be a unit dose of a liquid or powder medicament, drug or vaccine as discussed further hereinbelow. One end of the passage is sealed with a pierceable closure which may be formed during molding of the cartridge and the opposed end of the cartridge passage opposite the outlet of the medicament delivery device is sealed with a burstable membrane, preferably comprising a thin sheet of polyolefin or a polyolefin blend or copolymer having a thickness between 0.3 and 1.5 mils and a burst pressure of between 1.2 and 10 atmospheres, more preferably less than 5 atmospheres and most preferably between 1.5 and 4 atmospheres. The term polyolefin is understood to mean a polymer containing olefin units such as, for example, ethylene, propylene or1-butene units or any other alpha-olefin. Polyolefin as used herein includes polyethylene, polypropylene, ethylene- .alpha. olefin copolymer, wherein the alpha olefin having from 3 to 20, preferably 4 to 8 carbon atoms, polyolefin copolymers made by polymerizing olefins in the presence of a metallocene catalyst, ethylene-vinyl acetate copolymer, ethylene-ethyl acrylate copolymer, and ethylene-methyl acrylate copolymer. In particular, it is desirable to use polyethylene, such as low-density, linear-low-density, very-low-density, medium-density, or high-density polyethylene, or polypropylene, such as a polypropylene homopolymer, ethylene-propylene copolymer, or ethylene-propylene block copolymer. In the most preferred embodiment, the end of the cartridge at the outlet of the delivery device is convex or frustoconical surrounding the passage and a polymeric film is stretched taut over the convex surface and bonded or fused to the convex surface, thereby avoiding wrinkles or bulges in the burstable membrane which may adversely affect the consistency of the emitted dose of the delivery device.
- The medicament respiratory delivery device of this invention further includes a piercing element movable to pierce the pierceable closure of the cartridge and a manually compressible pressure actuator which delivers fluid under pressure through the housing inlet upon piercing of the pierceable closure, thereby rupturing the burstable membrane and expressing the medicament in the passage entrained in fluid to the outlet of the delivery device. In the most preferred embodiment, the piercing element pierces the pierceable closure prior to delivery of sufficient pressure to the burstable membrane to rupture the membrane. In the preferred embodiment, the piercing element includes an actuator portion and a shaft portion having a piercing end and the cartridge includes an integral tubular portion coaxially aligned with the pierceable closure which receives the piercing end of the shaft and which guides the piercing end of the piercing element. In this embodiment, the actuator portion of the piercing element is located within the pressure actuator, such that actuation of the pressure actuator also moves the shaft portion of the piercing element to pierce the pierceable closure.
- In the preferred embodiment of the medicament respiratory delivery device of this invention, the housing is comprised of two opposed thermoformed thermoplastic sheets bonded together, wherein the sheets have formed therebetween a central chamber, an inlet communicating with the chamber, a collapsible or compressible pressure actuator having an outlet communicating with the inlet to the chamber and an inlet opposite the inlet to the chamber preferably including a generally conical diffuser portion. The medicament cartridge is thereby encapsulated between the thermoformed thermoplastic bonded sheets forming the housing chamber. In the disclosed embodiment, the pressure actuator is bulb-shaped, preferably symmetrical with respect to the axis of the inlet and outlet of the chamber; however, the pressure actuator may also be a bellows-type pressure actuator either symmetrical with respect to the axis of the chamber inlet and outlet or extending from either of the thermoformed sheets. Where the pressure actuator is bulb-shaped or spherical, the acuator portion of the piercing element is bow-shaped having a concave arcuate portion generally conforming to the bulb-shape of the pressure actuator and a concave arcuate portion connected to or integral with the ends of the concave arcuate portion and the shaft portion is connected to the end of the concave portion, such that compression collapsing of the bulb-shaped pressure actuator collapses the actuator portion of the piercing element, driving the piercing end of the shaft through the pierceable closure of the capsule and deliver fluid under pressure to the cartridge passage, rupturing the burstable membrane and expressing entrained medicament through the outlet of the delivery device.
- As set forth above, the medicament respiratory delivery device of this invention may be utilized to aerosolize any medicament, drug or vaccine, referred to herein generically as a medicament, including liquid, powder or even gaseous medicaments. For example, the cartridge may contain a unit dose of a liquid or powder medicament or the bulb may be filled with a liquid, such as a diluent or medicament, and the cartridge may be filled with a powder medicament, wherein the powder medicament is simultaneously reconstituted by a diluent, for example, and expressed by the medicament respiratory delivery device of this invention to the respiratory system of a user or patient.
- The preferred embodiments of the medicament respiratory delivery device of this invention are particularly, but not exclusively, adapted for pulmonary, intranasal or buccal medicament delivery of a liquid or powder medicament, wherein the patient's inspiratory flowrate is not the driving force behind the delivery of the medicament. In the most preferred embodiment, the burstable membrane is formed of a preferentially oriented polyolefin film, preferably a uniaxially oriented polyethylene film having a thickness of about 1 mil and having a burst pressure of less than 5 atmospheres. Polyolefin films can be oriented by drawing in one or both mutually perpendicular directions in the plane of the film to impart strength thereto using methods known in the art. Oriented polyolefin films include machine direction and transverse direction orientation. Oriented polyolefin films include uniaxially or biaxially oriented films, with uniaxially oriented films being preferred. Uniaxially-oriented films have properties to their advantage for use as the burstable membrane, including relatively high stiffness, as indicated by the tensile modulus in a particular direction, usually the machine direction, compared to the transverse direction. Properties of the oriented polyolefin film can be dependent to a certain degree on the particular process conditions under which the polyolefin film was manufactured. For example, a stiffer film with lower transverse burst pressure properties would result from an orientation process incorporating a larger machine direction orientation draw ratio. Thus, oriented polyolefins films can be tailored to provide an appropriate burst pressure property within a preferred film thickness range. However, the burstable film may also be formed from various polymers, including cast polyethylene and polyethylene copolymers and scored or embossed polypropylene, acetate or polycarbonate. The medicament respiratory delivery of this device consistently delivers a predetermined quantity or dose of medicament to the respiratory system, is relatively simple and inexpensive to manufacture, and preferably is disposable following use. Other advantages and meritorious features of the medicament respiratory delivery device of this invention will be more fully understood from the following description of the preferred embodiments, the claims and the appended drawings, a brief description of which follows.
- FIG. 1 is a perspective view of a medicament cartridge for the medicament respiratory delivery device of this invention;
- FIG. 2 is a top perspective view of a preferred embodiment of the medicament respiratory delivery device of this invention;
- FIG. 3 is a side cross-sectional view of FIG. 2 in the direction of view arrows3-3;
- FIG. 4 is a side cross-sectional view of the medicament respiratory delivery device as shown in FIG. 3 during actuation of the device;
- FIG. 5 is a perspective view of the piercing element shown in FIG. 2;
- FIG. 6 is a side cross-sectional view of FIG. 2 wherein the cartridge includes a powder medicament and the bulb includes a liquid diluent; and
- FIG. 7 illustrates the medicament respiratory delivery device of FIG. 4 during actuation of the pressure actuator.
- FIG. 1 illustrates a preferred embodiment of the
medicament cartridge 20 for the embodiment of the medicamentrespiratory delivery device 22 illustrated in FIG. 2. Thecartridge 20 includes abody 24 having opposedends passage 30 extending through the opposed ends. In this embodiment, oneend 26 serves as the outlet end and the opposedend 28 serves as the inlet end as described further below. Theoutlet end 26 includes aburstable membrane 32 as described above and theinlet end 28 includes apierceable closure 34 as shown in FIGS. 3 and 4. In the preferred embodiment, theinlet end 28 further includes atubular guide 36 for the piercing element as described herein below. The body portion further includes a generally V-shapedgroove 38 for ease of handling. - In the preferred embodiment of the
medicament cartridge 20, the outlet end 26 of thebody 24 is convex or frustoconical surrounding thepassage 30 and theburstable membrane 32 comprises a thin polyolefin film which is stretched taut over theconvex end 26 and bonded to the convex end, thereby avoiding wrinkles in theburstable membrane 32 which may adversely affect the consistency of the emitted dose from the medicament respiratory delivery device, particularly at lower pressures. In the preferred embodiment, theburstable membrane 32 is formed from a thin sheet or film of polyolefin or a polyolefin copolymer, most preferably polyethylene or a polyethylene copolymer having a thickness of between 0.3 and 1.5 mils. and a burst pressure of between 1.2 and 10 atmospheres, more preferable less than 5 atmospheres and most preferably between 1.5 and 4 atmospheres. The film is heat bonded or fused to theconvex surface 26 of the outlet end of thebody 24. In the most preferred embodiment, the burstable membrane is formed from a thin preferentially or uniaxially oriented polyethylene film as discussed further below. - The opposed end of the
passage 30 is sealed with apierceable closure 34 as shown in FIGS. 3 and 4 and atubular guide 36 is perpendicular to thepierceable closure 34 and coaxial with thepassage 30. Thepierceable closure 34 may be formed of any suitable material which may be pierced during actuation of the medicament respiratory delivery device. In a most preferred embodiment, thebody 24 of the cartridge is formed of the same or a chemically similar polymer as theburstable membrane 32 and thetubular guide 36 andpierceable closure 34 is formed during injection molding of thecartridge body 24. Thus, thebody 24,pierceable closure 34 andtubular extension 36 may, for example, be formed of polyolefin polyethylene or a polyolefin copolymer including polyethylene. Included are metallized films of polyolefins. - The embodiment of the medicament respiratory delivery device shown in FIG. 2 and the following figures may be formed from opposed
thermoformed thermoplastic sheets medicament cartridge 20 described hereinbelow. In the disclosed embodiment, the housing formed by thethermoformed thermoplastic sheets intermediate chamber 44 which encapsulates thecartridge 20, the housing having aninlet 46 and anoutlet 48 which are preferably coaxially aligned with thepassage 30 through the cartridge and thus also coaxially aligned with theburstable membrane 32 andpierceable closure 34 as best shown in FIGS. 3 and 4. In the disclosed embodiment, theoutlet 48 includes a generallyconical diffuser portion 50 integrally formed between thesheets - The disclosed embodiment of the medicament
respiratory delivery device 22 of this invention further includes a manuallycompressible pressure actuator 52 and a piercingelement 54. In the preferred embodiment of the medicament respiratory delivery device of this invention, thepressure actuator 52 and the piercingelement 54 cooperate to first pierce thepierceable closure 34 of the medicament cartridge and then deliver fluid under pressure through the pierced opening, as shown in FIG. 4, to burst theburstable membrane 32 and express the medicament in thepassage 30 through theoutlet 48 as described hereinbelow. In the disclosed embodiment, thepressure actuator 52 is bulb-shaped and integrally formed between thesheets pressure actuator 52 is generally spherical and concentric with theaxis 56 of thecylindrical passage 30 through the cartridge. However, as set forth above, the pressure actuator may be a separate collapsible bulb or bellows-type actuator (not shown) or the pressure actuator may extend from either of thesheets element 54 now described. - The disclosed embodiment of the piercing
element 54 includes a bow-shapedactuator portion 58 and ashaft portion 60 having an enlarged sharp piercingend 62. As best shown in FIGS. 3 to 5, the bow-shapedactuator portion 58 includes aconvex portion 64, which generally conforms to the inside shape of thespherical bulb 52, andconcave portions 66 integral with the ends of theconvex portions 64 forming a bow-shape and theshaft 60 is attached to the end of theconcave portions 58, as best shown in FIG. 5. The piercingelement 54 may be formed from a suitable resilient flexible polymer such as polyethylene, polypropylene, etc. by injection molding. - As set forth above, the housing of the medicament
respiratory delivery device 22 may be vacuum formed from various thermoplastic polymers, including polyethylene, polypropylene, acetate, polycarbonate, etc. As will be understood, thesheets cartridge 20 and the piercingelement 54 is then assembled into one of the vacuum formed sheet halves and the vacuum formed sheets may then be heat fused together around the periphery as shown. As set forth above, thecartridge 20 may be filled with any suitable medicament, such as theliquid medicament 70 shown in FIG. 3. The cartridge may be filled with medicament by injection molding thebody 24 and thepierceable closure 34 andintegral guide tube 36. The medicament is then inserted into the cartridge through theopen exit end 26 through thepassage 30. Finally, theburstable membrane 32 is affixed over thefrustoconical end 26 of the cartridge by stretching the film and heat bonding or fusing the film to theend 26 of the cartridge. Alternatively, the burstable membrane may be adhesively bonded to theend 26 of the cartridge. - Having described one preferred embodiment of the medicament
respiratory delivery device 22 and the method of making same, the operation of the medicament respiratory delivery device will now be described with reference to FIGS. 3 and 4. As shown in FIG. 3, thepassage 30 in thecartridge 20 includes aliquid medicament 70. The piercingend 62 of theshaft 60 is received in thetubular guide portion 36 of the cartridge adjacent to thepierceable closure 34. To actuate the device, the user compresses thepressure actuator 52 as shown byarrows 72 in FIG. 4. As thepressure actuator 52 is compressed, it engages theconvex portion 64 of theactuator portion 58 of the piercing member as shown in FIG. 4, driving theshaft portion 60 to the left in FIG. 4, thereby driving the piercingportion 62 through thepierceable closure 34, delivering air under pressure through the tubular portion into thepassage 30 of thecartridge 20, substantially simultaneously rupturing theburstable membrane 32 with a relatively modest pressure and thereby expressing theliquid medicament 70 through the bursted membrane into thediffusor 50 as shown byarrows 74 where it is received by the respiratory system of the patient or user. - FIGS. 6 and 7 illustrate an alternative use of the medicament
respiratory delivery device 22, wherein thecartridge 20 is filled with apowder medicament 76 and theactuator portion 52 of the housing includes a liquid 78, such as a diluent or a second medicament. It is common practice to store dry or lypholized medicaments in powder form in a sealed vial to increase the shelf life of the medicament and reduce storage space. Such dry medicaments are conventionally reconstituted by adding a liquid, such as a diluent, which is injected into the vial through a syringe. Thecartridge 20 of this invention is sealed against moisture and thus will maintain a powder medicament for an extended period of time. The medicament respiratory delivery device of this invention may thus be used to simultaneously reconstitute and express a powder medicament by storing liquid in the bulb orblister 52, which is also sealed between thesheets - The operation of the
medicament delivery device 22 shown in FIGS. 6 and 7 is essentially identical to the operation of the device as described above in regard to FIGS. 3 and 4. That is, the user compresses the bulb-shapedactuator 52 as shown byarrows 72, which compresses theconvex portion 64 of the piercingelement 54, which drives the piercingend 62 of theshaft portion 60 through thepierceable closure 34 and simultaneously delivers the liquid 78 and gas into thepassage 30 of the cartridge and ruptures theburstable membrane 32. Where the liquid 78 is a diluent, the diluent simultaneously reconstitutes thepowder medicament 76 and the reconstituted liquid medicament is then expressed into thediffuser portion 50 of the medicament delivery device as shownarrows 80 to the respiratory system of the user. - As will now be understood, the medicament respiratory delivery device of this invention may be utilized to delivery various substances to the respiratory system of the user including medicaments, drugs and vaccines via the nasal, pulmonary or buccal routes used in the prevention, diagnosis, alleviation, treatment or cure of diseases. These substances may include, for example, (i) drugs such as Anti-Angiogenesis agents, Antisense, an to-ulcer, butorphanol, Calcitonin and analogs, COX-II inhibitors, desmopressin and analogs, dihydroergotamie, Dopamine agonists and antagonists, Enkephalins and other opioid peptides, Growth hormone and analogs (including growth hormone releasing hormone), Growth hormone antagonists, IgE suppressors, Insulin, insulinotropin and analogs, Ketamine, Kytril, Leutenizing hormone releasing hormone and analogs, lidocaine, metoclopramide, Midazolam, Narcotic analgesics, neuraminidase inhibitors, nicotine, Non-steroid an to-inflammatory agents, Oligosaccharides, ondansetron, Parathyroid hormone and analogs, Parathyroid hormone antagonists, Prostaglandin antagonists, Prostaglandins, Recombinant soluble receptors, scopolamine, Serotonin agonists and antagonists, Sildenafil, Terbutaline, vasopressin, (ii) Vaccines with or without carriers/adjuvants such as prophylactics and therapeutic antigens (including but not limited to subunit protein, peptide and polysaccharide, polysaccharide conjugates, toxoids, genetic based vaccines, live attenuated, reassortant, inactivated, whole cells, viral and bacterial vectors) in connection with arthritis, cholera, cocaine addiction, HIB, meningococcus, measles, mumps, rubella, varicella, yellow fever, Respiratory syncytial virus, pneumococcus, streptococcus. Typhoid, influenza, hepatitis, including hepatitis A, B, C and E, polio, HIV, parainfluenza, rotavirus, CMV, chlamydia, non-typeable haemophilus, moraxella catarrhalis, human papilloma virus, tuberculosis including BCG, gonorrhea, asthma, atheroschlerosis, malaria, otitis media,E-coli, Alzheimers, H. Pylori, salmonella, diabetes, cancer and herpes simplex, and (iii) other substances in all of the major therapeutics such as Agents for the common cold, Anti-addiction, anti-infectives, analgesics, anesthetics, anorexics, antiarthritics, anti-allergy agents, antiasthmatic agents, anticonvulsants, antidepressants, antidiabetic agents, anti-depressants, anti-diuretics, anti-emetics, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antineuseants, antieoplastics, anti-obesity, antiosteoporeteic, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antagonists, bone stimulating agents, central nervous system stimulants, hormones, hypnotics, immunosuppressives, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, rhinitis treatment, sedatives, sexual hypofucnction, tranquilizers and vitamins including B12.
- Computer modeling and testing of a prototype cartridge having a cylindrical bore or passage filled with a powder and various thin rupturable membranes indicated that a preferentially or uniaxially oriented polyethylene film having a thickness of about0.5 mils resulted in an emitted dose of about 97% of powder from the passage with a burst pressure of about 3 atmospheres. Burst tests of burstable membranes were conducted by the applicant using a syringe to deliver gas under pressure to a cartridge having burstable membranes sealing both ends of the passage. The cartridge was placed in a test fixture simulating a medicament respiratory delivery device. The membranes of the cartridge each had a surface area of 0.049 in2 (3 mm diameter). The stopper was moved through the barrel under controlled conditions at 25 in/min and the burst pressure (force divided by area) and emitted dose (i.e. percentage of powder emitted from the passage, KPLC assay) was measured. Computer modeling indicated that the most preferred embodiment of the cartridge included a burstable membrane only at the outlet or exit end of the cartridge. Thus, the medicament delivery device of this invention results in the greatest emitted dose from the
passage 30 because theinlet closure 34 is ruptured by piercing prior to delivery of fluid to the passage. Prototype testing by the applicant of other burstable membranes as described above indicated that the next preferred burstable membrane film was acast 50/50 polyolefin copolymer of ethylene and methylacrylate and having a thickness of about one mil and a burst pressure of 2 atmospheres, wherein the emitted dose was about 95%. The applicant also tested a polyethylene film having a thickness of about 0.9 mil wherein the polyethylene film had a checkerboard embossment having a burst pressure of 3 atmospheres, wherein the emitted dose was about 91%. It is also believed that the films formed from other polymers may be utilized for theburstable membrane 32 including, for example, polypropylene, acetate and polycarbonate. However, it is believed that such other films should also be scored or embossed to reduce the burst pressure of the burstable membrane. As set forth above, thepierceable closure 34 may be formed of various pierceable films or sheets. In the most preferred embodiment, thepierceable closure 34 is integrally formed with thebody 24 of the cartridge, such as by injection molding. Thus, where theburstable membrane 32 is formed from a film of a polyolefin, most preferably polyethylene or polyethylene copolymer or blend and heat fused to theend 26 of the cartridge, the cartridge is most preferably formed from a polyethylene or a polyethylene copolymer, such that the pierceable membrane may also be formed of polyethylene. Thethermoformed sheets - Having described preferred embodiments of the medicament respiratory delivery device of this invention, it will be understood that various modifications may be made within the purview of the appended claims. For example, the
passage 30 through the cartridge is preferably generally cylindrical; however, the passage may also include other shapes or configurations including, for example, an hourglass shape.
Claims (22)
1. A medicament respiratory delivery device, comprising:
a housing having a chamber therein, a housing inlet communicating with said chamber, and a housing outlet generally coaxially aligned with said housing inlet;
a cartridge located within said chamber having opposed ends, a passage extending through said cartridge through said opposed ends aligned with said housing inlet and housing outlet, and a medicament in said passage;
a pierceable closure sealing said passage opposite said housing inlet;
a burstable membrane sealing said passage opposite said housing outlet;
a piercing element movable relative to said housing to pierce said pierceable closure; and
a pressure actuator delivering fluid under pressure to said housing inlet upon piercing of said pierceable closure to burst said burstable membrane, thereby expressing medicament in said passage entrained in fluid to said housing outlet.
2. The medicament respiratory delivery device as defined in claim 1 , wherein said pressure actuator is a flexible collapsible element having an outlet communicating with said housing inlet and at least a portion of said piercing element is located within said flexible collapsible element.
3. The medicament respiratory delivery device as defined in claim 2 , wherein said flexible collapsible element is bulb-shaped and said piercing element includes a bow-shaped portion located within said bulb-shaped flexible collapsible element and a relatively sharp piercing portion, whereby collapsing of said bulb-shaped flexible collapsible element compresses said bow-shaped portion of said piercing element and extends said piercing portion to pierce said pierceable closure.
4. The medicament respiratory delivery device as defined in claim 1 , wherein said pressure actuator moves said piercing element to pierce said pierceable closure prior to delivery of sufficient pressure to said housing inlet to burst said burstable membrane.
5. The medicament respiratory delivery device as defined in claim 1 , wherein said piercing element includes a shaft having a pointed end and said cartridge includes a tubular portion coaxially aligned with said passage receiving said pointable end and at least a portion of said shaft, said tubular portion guiding said pointed end of said piercing element to pierce said pierceable closure upon movement of said shaft.
6. The medicament respiratory delivery device as defined in claim 5 , wherein said pressure actuator includes a flexible collapsible bulb having an outlet communicating with said housing inlet, and said piercing element includes a bow-shaped portion located within said bulb connected to said shaft, moving said shaft to pierce said pierceable closure upon collapse of said bulb.
7. The medicament respiratory delivery device as defined in claim 1 , wherein said housing comprises opposed thermoformed thermoplastic bonded sheets having formed therebetween a tubular outlet portion defining said housing outlet, a generally cylindrical chamber portion defining said chamber receiving said cartridge in sealed relation and an integral flexible collapsible blister defining said pressure actuator.
8. The medicament respiratory delivery device as defined in claim 5 , wherein said piercing element is at least partially located within said blister.
9. The medicament respiratory delivery device as defined in claim 8 , wherein said piercing element includes a bow-shaped portion located within said blister and a shaft connected to said bow-shaped portion having a piercing end, whereby collapsing of said blister actuates said bow-shaped portion and extends said shaft to pierce said pierceable closure.
10. The medicament respiratory delivery device as defined in claim 9 , wherein said cartridge includes an integral tubular portion coaxially aligned with said passage and said shaft is received in said tubular portion, guiding said piercing end to said pierceable closure.
11. The medicament respiratory delivery device as defined in claim 9 , wherein said bow-shaped portion of said piercing element includes a concave portion generally conforming to the shape of said blister having opposed end portions and concave portions integral with said end portions, and said shaft is connected to said convex portions.
12. A medicament respiratory delivery device, comprising:
a housing comprised of opposed thermoformed thermoplastic bonded sheets, said sheets having formed therebetween a chamber, an inlet communicating with said chamber, a collapsible pressure actuator having an outlet communicating with said inlet of said chamber and an outlet communicating with said chamber opposite said inlet of said chamber;
a medicament cartridge in said chamber having a body encapsulated by said sheets, said body having opposed first and second ends, a passage extending through said body through said opposed first and second ends, a pierceable closure sealing said passage at said first end opposite said inlet of said chamber, and a burstable membrane sealing said passage at said second end of said body opposite said outlet of said chamber; and
a piercing element having a piercing end adjacent said pierceable closure movable relative to said body of said cartridge to pierce said pierceable closure upon actuation of said collapsible pressure actuator delivering fluid under pressure to said passage of said cartridge, thereby rupturing said burstable membrane and expressing medicament in said passage entrained in fluid to said outlet.
13. The medicament respiratory delivery device as defined in claim 12 , wherein said collapsible pressure actuator is generally spherical and generally symmetrical relative to said outlet of said collapsible pressure actuator.
14. The medicament respiratory delivery device as defined in claim 12 , wherein said piercing element is at least partially located within said collapsible pressure actuator.
15. The medicament respiratory delivery device as defined in claim 14 , wherein said piercing element includes a bow-shaped portion located within said collapsible pressure actuator and a shaft portion connected to said bow-shaped portion having said piercing end, whereby actuation of said collapsible pressure actuator collapses said bow-shaped portion of said piercing element, extending said shaft to pierce said pierceable closure of said cartridge.
16. The medicament respiratory delivery device as defined in claim 15 , wherein said collapsible pressure actuator is bulb-shaped and symmetrical relative to said outlet of said collapsible pressure actuator.
17. The medicament respiratory delivery device as defined in claim 12 , wherein said body of said cartridge includes an integral tubular portion coaxially aligned with said passage receiving said piercing end of said piercing element and guiding said piercing element to pierce said pierceable closure.
18. The medicament respiratory delivery device as defined in claim 12 , wherein said body of said cartridge is generally cylindrical and said chamber formed between said opposed thermoformed thermoplastic sheets generally cylindrical, conforming to the shape of said body of said cartridge.
19. A medicament respiratory delivery device, comprising:
a housing formed of two opposed thermoformed thermoplastic bonded sheets, said sheets having formed therebetween a chamber, an inlet communicating with said chamber, a bulb-shaped collapsible pressure actuator having an outlet communicating with said inlet of said chamber, and an outlet communicating with said chamber opposite said inlet of said chamber;
a medicament cartridge in said chamber having a body encapsulated between said opposed thermoformed thermoplastic bonded sheets, said body having opposed first and second ends, a passage extending through said body through said first and second ends, a pierceable closure sealing said passage at said first end of said body opposite said inlet of said chamber, and a burstable membrane sealing said passage at said second end opposite said outlet of said chamber; and
a piercing element having an actuator portion located within said bulb-shaped collapsible pressure actuator and a shaft connected to said actuator portion having a distal piercing end adjacent said pierceable closure of said cartridge, whereby collapse of said bulb-shaped collapsible pressure actuator engages said actuator portion of said piercing element to extend said shaft, piercing said pierceable closure and delivering fluid under pressure to said passage of said cartridge, rupturing said burstable membrane and delivering medicament to said outlet communicating with said chamber.
20. The medicament respiratory delivery device as defined in claim 19 , wherein said actuator portion of said piercing element is bow-shaped.
21. The medicament respiratory delivery device as defined in claim 19 , wherein said burstable membrane is a polyethylene sheet having a thickness of between 0.3 and 1.5 mils stretched taut over said second end of said cartridge.
22. The medicament respiratory delivery device as defined in claim 21 , wherein said polyethylene sheet is uniaxially oriented.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/879,714 US6443152B1 (en) | 2001-01-12 | 2001-06-12 | Medicament respiratory delivery device |
PCT/US2002/000570 WO2002056950A2 (en) | 2001-01-12 | 2002-01-09 | Medicament respiratory delivery device |
JP2002557457A JP4343530B2 (en) | 2001-01-12 | 2002-01-09 | Drug delivery device for respiratory organs |
AT02717311T ATE281200T1 (en) | 2001-01-12 | 2002-01-09 | DEVICE FOR ADMINISTRATION OF MEDICATION INTO THE RESPIRATORY TRACT |
DE60201815T DE60201815T2 (en) | 2001-01-12 | 2002-01-09 | DEVICE FOR THE ADMINISTRATION OF MEDICAMENTS IN THE RESPIRATORY PATHS |
EP02717311A EP1349598B1 (en) | 2001-01-12 | 2002-01-09 | Medicament respiratory delivery device |
ES02717311T ES2229113T3 (en) | 2001-01-12 | 2002-01-09 | DRUG RESPIRATORY AMINISTRATION DEVICE. |
US10/233,863 US7270127B2 (en) | 2001-01-12 | 2002-09-03 | Medicament respiratory delivery device |
US11/842,470 US20080006269A1 (en) | 2001-01-12 | 2007-08-21 | Medicament Respiratory Delivery Device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/758,776 US6722364B2 (en) | 2001-01-12 | 2001-01-12 | Medicament inhalation delivery devices and methods for using the same |
US09/879,714 US6443152B1 (en) | 2001-01-12 | 2001-06-12 | Medicament respiratory delivery device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/758,776 Continuation-In-Part US6722364B2 (en) | 2001-01-12 | 2001-01-12 | Medicament inhalation delivery devices and methods for using the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/233,863 Continuation US7270127B2 (en) | 2001-01-12 | 2002-09-03 | Medicament respiratory delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020092524A1 true US20020092524A1 (en) | 2002-07-18 |
US6443152B1 US6443152B1 (en) | 2002-09-03 |
Family
ID=27116576
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/879,714 Expired - Lifetime US6443152B1 (en) | 2001-01-12 | 2001-06-12 | Medicament respiratory delivery device |
US10/233,863 Expired - Lifetime US7270127B2 (en) | 2001-01-12 | 2002-09-03 | Medicament respiratory delivery device |
US11/842,470 Abandoned US20080006269A1 (en) | 2001-01-12 | 2007-08-21 | Medicament Respiratory Delivery Device |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/233,863 Expired - Lifetime US7270127B2 (en) | 2001-01-12 | 2002-09-03 | Medicament respiratory delivery device |
US11/842,470 Abandoned US20080006269A1 (en) | 2001-01-12 | 2007-08-21 | Medicament Respiratory Delivery Device |
Country Status (7)
Country | Link |
---|---|
US (3) | US6443152B1 (en) |
EP (1) | EP1349598B1 (en) |
JP (1) | JP4343530B2 (en) |
AT (1) | ATE281200T1 (en) |
DE (1) | DE60201815T2 (en) |
ES (1) | ES2229113T3 (en) |
WO (1) | WO2002056950A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004108205A1 (en) * | 2003-06-02 | 2004-12-16 | Becton Dickinson And Company | Medicament microdevice delivery system with a cartridge |
US20050000514A1 (en) * | 2001-01-12 | 2005-01-06 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
EP1506792A2 (en) * | 2003-08-14 | 2005-02-16 | Nathaniel Hughes | Liquid medicament delivery system |
US20060030827A1 (en) * | 2004-07-14 | 2006-02-09 | Medical Components, Inc. | Luer cleaner |
WO2007018568A1 (en) | 2005-07-20 | 2007-02-15 | Manta Devices, Llc | Inhalation device |
US20080114304A1 (en) * | 2006-11-13 | 2008-05-15 | Medical Components, Inc | Syringe for sequential expression of different liquids and method of using same |
US20080224336A1 (en) * | 2007-03-16 | 2008-09-18 | Vapotherm, Inc. | Water spike system |
US20090205151A1 (en) * | 2008-02-19 | 2009-08-20 | Medical Components, Inc | Luer Cleaner with Self-Puncturing Reservoir |
US20130233313A1 (en) * | 2010-11-29 | 2013-09-12 | Sanofi-Aventis Deutschland Gmbh | Medicated Module for an Inhaler |
US20150126898A1 (en) * | 2012-08-30 | 2015-05-07 | Mystic Pharmaceuticals, Inc. | Fully Self-Contained Unit Dose Devices for Allergy Skin Testing |
US20150217065A1 (en) * | 2009-05-18 | 2015-08-06 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
US20160101246A1 (en) * | 2014-10-10 | 2016-04-14 | Solaeromed Inc. | Apparatus and methods for producing and delivering a vapour medicament |
CN106163598A (en) * | 2014-04-28 | 2016-11-23 | 菲利普莫里斯生产公司 | Nicotine powder inhalator |
CN106170313A (en) * | 2014-04-28 | 2016-11-30 | 菲利普莫里斯生产公司 | Band fragrance nicotine powder inhalator |
US9919115B2 (en) | 2007-07-06 | 2018-03-20 | Manta Devices, Llc | Dose delivery device for inhalation with first and second portions to open a dose chamber |
CN109069776A (en) * | 2016-05-31 | 2018-12-21 | 菲利普莫里斯生产公司 | With the apparatus for aerosol creation for piercing through sub-assembly |
US10632268B2 (en) | 2005-07-20 | 2020-04-28 | Manta Devices, Llc | Inhalation device |
US20200197630A1 (en) * | 2017-06-06 | 2020-06-25 | Aptar France Sas | Fluid or powdery product dispensing device |
US11147936B2 (en) | 2014-05-02 | 2021-10-19 | Manta Devices, Llc | Dose delivery device with cover connected to dose chamber seal |
US20210361884A1 (en) * | 2018-05-08 | 2021-11-25 | Akroswiss Ag | Bi-dose nasal spray |
US20210393897A1 (en) * | 2018-11-19 | 2021-12-23 | Shin Nippon Biomedical Laboratories, Ltd, | Medicine dispensing device and method for manufacturing same |
US11224704B2 (en) | 2007-07-06 | 2022-01-18 | Manta Devices, Llc | Dose delivery device for inhalation |
US11497251B2 (en) | 2016-05-31 | 2022-11-15 | Altria Client Services Llc | Aerosol generating device with piercing assembly |
EP4114485A4 (en) * | 2020-03-05 | 2024-03-06 | Sipnose Ltd | DEVICES AND METHOD FOR DELIVERING A SUBSTANCE INTO A BODY CAVITY |
US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19961300A1 (en) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Storage system for medicinal products in powder form and inhaler equipped with them |
US6457471B1 (en) * | 2000-06-30 | 2002-10-01 | Medihale Ltd. | Dual-purpose medical device for upper airway treatment and methods for using same |
US6443152B1 (en) * | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
US6782887B2 (en) * | 2001-01-12 | 2004-08-31 | Becton, Dickinson And Company | Medicament respiratory delivery device and cartridge |
US6722364B2 (en) * | 2001-01-12 | 2004-04-20 | Becton, Dickinson And Company | Medicament inhalation delivery devices and methods for using the same |
US6644309B2 (en) * | 2001-01-12 | 2003-11-11 | Becton, Dickinson And Company | Medicament respiratory delivery device and method |
US6766799B2 (en) * | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
GB0215904D0 (en) * | 2002-07-09 | 2002-08-21 | Team Holdings Uk Ltd | Drug delivery system and method |
DE10244795A1 (en) * | 2002-09-26 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
US6941947B2 (en) * | 2002-12-18 | 2005-09-13 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
ATE510174T1 (en) | 2003-05-21 | 2011-06-15 | Alexza Pharmaceuticals Inc | IMPACT LIT INDEPENDENT HEATING UNIT |
US8038639B2 (en) * | 2004-11-04 | 2011-10-18 | Baxter International Inc. | Medical fluid system with flexible sheeting disposable unit |
WO2005102058A2 (en) * | 2004-04-23 | 2005-11-03 | Mystic Pharmaceuticals, Inc. | Multiple unit dose drug delivery system |
US20050263153A1 (en) * | 2004-05-28 | 2005-12-01 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
USD548833S1 (en) | 2004-05-28 | 2007-08-14 | Quadrant Technologies Limited | Dry powder inhaler |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
BE1015883A3 (en) * | 2004-06-08 | 2005-10-04 | Occhio | Method and device for release powder dry. |
WO2006022714A1 (en) | 2004-08-12 | 2006-03-02 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
GB0418738D0 (en) * | 2004-08-23 | 2004-09-22 | 3M Innovative Properties Co | Medicinal aerosol formulation receptacle and production thereof |
GB0426780D0 (en) * | 2004-12-07 | 2005-01-12 | 3M Innovative Properties Co | Pressurized inhalation devices |
GB0428169D0 (en) * | 2004-12-23 | 2005-01-26 | 3M Innovative Properties Co | Pressurized inhalation devices |
GB2422786B (en) * | 2005-03-03 | 2007-05-23 | Bespak Plc | Dispenser |
US20070012316A1 (en) * | 2005-07-14 | 2007-01-18 | Joann Truza | Disposable compact rescue inhaler |
DE102005038619A1 (en) | 2005-08-16 | 2007-02-22 | Pari GmbH Spezialisten für effektive Inhalation | An inhalation therapy device with an ampoule for storing a medicament to be nebulised |
US7644821B2 (en) * | 2006-04-10 | 2010-01-12 | Poppack, Llc | Sealed product delivery unit with rupturing pump |
DE102006016903A1 (en) * | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | inhaler |
USD590057S1 (en) * | 2006-06-01 | 2009-04-07 | Cipla Limited | Inhaler |
JP2009543658A (en) * | 2006-07-14 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | Inhalation device and delivery device for administering dry powder medicine |
CA2886385A1 (en) | 2007-01-09 | 2008-07-17 | Mystic Pharmaceuticals, Inc. | Intranasal cartridge devices |
ES2594867T3 (en) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US8683995B2 (en) | 2007-05-16 | 2014-04-01 | Mystic Pharmaceuticals, Inc. | Dose dispensing containers |
JP5352583B2 (en) * | 2007-05-16 | 2013-11-27 | ミスティック ファーマシューティカルズ, インコーポレイテッド | Linkage container for unit dose administration |
US9248076B2 (en) | 2007-05-16 | 2016-02-02 | Mystic Pharmaceuticals, Inc. | Dose dispensing containers |
GB2449312B (en) * | 2007-05-18 | 2012-03-14 | Malvern Instr Ltd | Method and apparatus for dispersing a sample of particulate material |
US7963089B2 (en) * | 2007-09-14 | 2011-06-21 | Mystic Pharmaceuticals, Inc. | Deep draw container forming method |
US20090151716A1 (en) * | 2007-09-18 | 2009-06-18 | Robert Abrams | Semi-automatic emergency medication dose nebulizer |
US7836885B2 (en) * | 2007-09-18 | 2010-11-23 | Robert Abrams | Semi-automatic emergency medication dose nebulizer |
US8790366B2 (en) * | 2007-11-13 | 2014-07-29 | Alcon Research, Ltd. | Fan-shaped cannula for sealing ophthalmic incisions |
DE102007056462B4 (en) * | 2007-11-23 | 2011-10-27 | Pari Pharma Gmbh | Disposable ampoule for a device for generating aerosols |
GB2459257B (en) * | 2008-04-14 | 2012-12-19 | Alchemy Healthcare Ltd | Particulate dispenser |
US8517010B2 (en) | 2008-09-26 | 2013-08-27 | Stamford Devices Limited | Nebuliser system |
WO2010083042A1 (en) * | 2009-01-15 | 2010-07-22 | Manta Devices, Llc | Delivery device |
US8974771B2 (en) * | 2010-03-09 | 2015-03-10 | Penn-Century, Inc. | Apparatus and method for aerosol delivery to the lungs or other locations of the body |
WO2011116293A2 (en) | 2010-03-19 | 2011-09-22 | Manta Devices, Llc | Delivery device and related methods |
DK3184136T3 (en) | 2010-03-25 | 2021-08-23 | New Injection Systems Ltd | INJECTOR |
KR20140003582A (en) * | 2011-01-31 | 2014-01-09 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | Intranasal delivery devices |
CA2773480C (en) | 2011-04-05 | 2014-12-30 | Tyco Healthcare Group Lp | Buffering agent delivery system for anesthetic syringe |
US11103659B2 (en) | 2011-07-06 | 2021-08-31 | Manta Devices, Llc | Delivery device and related methods |
US9649454B2 (en) | 2012-05-03 | 2017-05-16 | Manta Devices, Llc | Delivery device and related methods |
EP2922588B1 (en) | 2012-11-23 | 2019-02-06 | New Injection Systems Ltd | Auto-injector assembly |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN205916436U (en) * | 2016-07-13 | 2017-02-01 | 深圳市合川医疗科技有限公司 | Bubble cap puncture component |
USD828653S1 (en) | 2016-12-14 | 2018-09-11 | Brandon Penland | Treatment applicator |
US10569069B2 (en) | 2016-12-14 | 2020-02-25 | Combat Comb, Llc | Applicator for treatments applied to animal skin |
GB201713899D0 (en) * | 2017-08-30 | 2017-10-11 | Indosys Ltd | Multi-dose medicament delivery device |
CA3090277A1 (en) | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
US11864953B2 (en) | 2020-01-23 | 2024-01-09 | Covidien Lp | Smoke evacuating tissue guard for tissue removal and other surgical procedures |
US11207057B1 (en) | 2020-08-07 | 2021-12-28 | Cyrano Medical, Inc. | Nasopharyngeal sample collection devices and methods |
GB202117016D0 (en) * | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2307986A (en) * | 1940-02-15 | 1943-01-12 | Bolte | Insufflator |
US3058464A (en) * | 1957-04-22 | 1962-10-16 | Baxter Laboratories Inc | Oxygenator |
US2946332A (en) * | 1957-12-23 | 1960-07-26 | Nysco Lab Inc | Insufflator |
US3625213A (en) | 1969-09-22 | 1971-12-07 | Scherer Corp R P | Dispenser with rupturing means |
US3949751A (en) * | 1970-03-03 | 1976-04-13 | Fisons Limited | Method and device for dispensing medicament to the body |
GB1338254A (en) * | 1970-03-25 | 1973-11-21 | Fisons Ltd | Powder blowing device |
US3934585A (en) * | 1970-08-13 | 1976-01-27 | Maurice David M | Method and apparatus for application of eye drops |
IT941426B (en) * | 1971-07-17 | 1973-03-01 | Isf Spa | SWIRL-CHAMBER INHALER FOR POWDER-SHAPING MEDICINAL SUBSTANCES |
SE7415243L (en) * | 1973-12-26 | 1975-06-27 | Ciba Geigy Ag | |
US3874380A (en) * | 1974-05-28 | 1975-04-01 | Smithkline Corp | Dual nozzle intranasal delivery device |
DE7916475U1 (en) | 1979-06-08 | 1979-10-18 | Hoechst Ag, 6000 Frankfurt | Spray applicator |
SE8502933D0 (en) | 1985-06-13 | 1985-06-13 | Leo Ab | Pipette |
US4723691A (en) | 1986-08-15 | 1988-02-09 | Minkevitch Joseph M | Powder dispenser |
DE3810262A1 (en) | 1988-03-25 | 1989-10-12 | Henning Berlin Gmbh | DEVICE FOR THE DOSED ADMINISTRATION OF A LIQUID MEDICINAL PRODUCT |
GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
US5239991A (en) | 1989-06-21 | 1993-08-31 | Fisons Plc | Disposable powder medicament inhalation device with peel-off cover |
US5328464A (en) * | 1990-04-24 | 1994-07-12 | Science Incorporated | Closed drug delivery system |
FR2667509B1 (en) | 1990-10-04 | 1995-08-25 | Valois | POWDER INHALER, DEVICE FOR PACKAGING POWDER MICRODOSES IN THE FORM OF BANDS SUITABLE FOR USE IN A POWDER INHALER, AND METHOD FOR MANUFACTURING SUCH BANDS. |
AU8720791A (en) | 1990-10-12 | 1992-05-20 | Novo Nordisk A/S | Disposable dispenser for powder |
US5331954A (en) | 1990-12-21 | 1994-07-26 | Novo Nordisk A/S | Device for nasal delivery of liquid medications |
ATE359842T1 (en) * | 1991-07-02 | 2007-05-15 | Nektar Therapeutics | DISPENSING DEVICE FOR MIST-FORMED MEDICATIONS |
US5601077A (en) | 1991-08-07 | 1997-02-11 | Becton, Dickinson And Company | Nasal syringe sprayer with removable dose limiting structure |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
DK198591D0 (en) * | 1991-12-10 | 1991-12-10 | Novo Nordisk As | APPARATUS |
EP0558879B1 (en) | 1992-03-04 | 1997-05-14 | Astra Aktiebolag | Disposable inhaler |
US5215221A (en) | 1992-05-07 | 1993-06-01 | The Procter & Gamble Company | Disposable unit dose dispenser for powdered medicants |
US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US5547131A (en) | 1992-12-04 | 1996-08-20 | Bespak Plc | Dispensing device with spray nozzle and driven piston |
IL108780A (en) * | 1993-02-27 | 1999-06-20 | Fisons Plc | Inhalation device |
TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
US5819730A (en) | 1993-06-09 | 1998-10-13 | Glaxo Wellcome Australia Ltd. | Device for administering pharmaceutical substances |
US5349947A (en) | 1993-07-15 | 1994-09-27 | Newhouse Michael T | Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow |
SE9400335D0 (en) * | 1994-02-02 | 1994-02-02 | Astra Ab | Powder mixing |
US5899880A (en) | 1994-04-08 | 1999-05-04 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
KR970706032A (en) | 1994-09-16 | 1997-11-03 | 그라함 브레레턴 | Inhalation Device |
SE9404439D0 (en) * | 1994-12-21 | 1994-12-21 | Astra Ab | Inhalation device |
US5571246A (en) * | 1995-02-16 | 1996-11-05 | Alldredge; Andrew L. | Collapsible metered dose inhaler |
US5513630A (en) | 1995-03-08 | 1996-05-07 | Century; Theodore J. | Powder dispenser |
JP3308425B2 (en) * | 1995-03-10 | 2002-07-29 | 株式会社ユニシアジェックス | Nasal administration device |
US5637087A (en) * | 1995-03-22 | 1997-06-10 | Abbott Laboratories | Prefilled, two-constituent syringe |
US6214255B1 (en) * | 1995-04-19 | 2001-04-10 | Capitol Specialty Plastics, Inc. | Desiccant entrained polymer |
JPH10510198A (en) | 1995-05-12 | 1998-10-06 | ジェネンテク・インコーポレイテッド | Coarse spray delivery of functional biological materials |
DE19518810A1 (en) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal applicator |
DE19523516C1 (en) | 1995-06-30 | 1996-10-31 | Asta Medica Ag | Inhaler for administering medication from blister packs |
US6209538B1 (en) | 1995-08-02 | 2001-04-03 | Robert A. Casper | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
SE9502799D0 (en) * | 1995-08-10 | 1995-08-10 | Astra Ab | Device in inhalers |
JPH11514254A (en) * | 1995-08-18 | 1999-12-07 | ファーマソル リミテッド | Spray applicator |
DE19533979A1 (en) | 1995-09-14 | 1997-03-20 | Alfred Von Schuckmann | Device for the dosed, airborne delivery of substances |
DE19535010C2 (en) * | 1995-09-21 | 1998-01-22 | Pelikan Produktions Ag | Use of a drop generator in a medical device for the metered delivery of a medicament to a fluid stream |
DE19545842C1 (en) | 1995-12-08 | 1996-10-10 | Schott Glaswerke | Modular ceramic cooking hob |
NZ324374A (en) * | 1996-01-03 | 1999-06-29 | Glaxo Group Ltd | Inhalation device |
NL1002078C2 (en) | 1996-01-12 | 1997-07-15 | Sumajow Holding B V | Dispenser for a therapeutic. |
US5797392C1 (en) | 1996-01-22 | 2001-01-09 | Direct Haler As | Inhaler |
IL126545A (en) | 1996-04-25 | 2003-09-17 | Astrazeneca Ab | Inhaler |
US5894967A (en) | 1996-10-28 | 1999-04-20 | The Procter & Gamble Company | Squeeze dispenser for powder |
SE9700422D0 (en) * | 1997-02-07 | 1997-02-07 | Astra Ab | Single dose inhaler II |
SE9700421D0 (en) * | 1997-02-07 | 1997-02-07 | Astra Ab | Single dose inhalation I |
US5881720A (en) | 1997-04-29 | 1999-03-16 | The Procter & Gamble Company | Method of delivering halotherapy |
US6267753B1 (en) * | 1997-07-15 | 2001-07-31 | Ti Kao | Robotic medicament dispenser |
US5941867A (en) * | 1997-07-15 | 1999-08-24 | Kao; Ti | Formulation of pharmaceutical solutions in free fall |
SE9800897D0 (en) | 1998-03-17 | 1998-03-17 | Astra Ab | Inhalation device |
WO1999056807A1 (en) | 1998-05-04 | 1999-11-11 | Glaxo Group Limited | Unit dose inhaler apparatus and method of delivery using same |
GB9810126D0 (en) * | 1998-05-13 | 1998-07-08 | Glaxo Group Ltd | |
US6070575A (en) * | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
US6606992B1 (en) * | 1999-06-30 | 2003-08-19 | Nektar Therapeutics | Systems and methods for aerosolizing pharmaceutical formulations |
UA75375C2 (en) * | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
US6644309B2 (en) * | 2001-01-12 | 2003-11-11 | Becton, Dickinson And Company | Medicament respiratory delivery device and method |
US7850663B2 (en) * | 2001-01-12 | 2010-12-14 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
US6782887B2 (en) * | 2001-01-12 | 2004-08-31 | Becton, Dickinson And Company | Medicament respiratory delivery device and cartridge |
US6443152B1 (en) * | 2001-01-12 | 2002-09-03 | Becton Dickinson And Company | Medicament respiratory delivery device |
US6722364B2 (en) * | 2001-01-12 | 2004-04-20 | Becton, Dickinson And Company | Medicament inhalation delivery devices and methods for using the same |
-
2001
- 2001-06-12 US US09/879,714 patent/US6443152B1/en not_active Expired - Lifetime
-
2002
- 2002-01-09 DE DE60201815T patent/DE60201815T2/en not_active Expired - Lifetime
- 2002-01-09 ES ES02717311T patent/ES2229113T3/en not_active Expired - Lifetime
- 2002-01-09 WO PCT/US2002/000570 patent/WO2002056950A2/en active IP Right Grant
- 2002-01-09 AT AT02717311T patent/ATE281200T1/en not_active IP Right Cessation
- 2002-01-09 JP JP2002557457A patent/JP4343530B2/en not_active Expired - Fee Related
- 2002-01-09 EP EP02717311A patent/EP1349598B1/en not_active Expired - Lifetime
- 2002-09-03 US US10/233,863 patent/US7270127B2/en not_active Expired - Lifetime
-
2007
- 2007-08-21 US US11/842,470 patent/US20080006269A1/en not_active Abandoned
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050000514A1 (en) * | 2001-01-12 | 2005-01-06 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
US8251958B2 (en) | 2001-01-12 | 2012-08-28 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
US7850663B2 (en) | 2001-01-12 | 2010-12-14 | Becton, Dickinson And Company | Medicament microdevice delivery system, cartridge and method of use |
WO2004108205A1 (en) * | 2003-06-02 | 2004-12-16 | Becton Dickinson And Company | Medicament microdevice delivery system with a cartridge |
EP1506792A2 (en) * | 2003-08-14 | 2005-02-16 | Nathaniel Hughes | Liquid medicament delivery system |
EP1506792A3 (en) * | 2003-08-14 | 2006-06-07 | Nathaniel Hughes | Liquid medicament delivery system |
US7857793B2 (en) | 2004-07-14 | 2010-12-28 | Medical Components Inc. | Luer cleaner |
US7993309B2 (en) | 2004-07-14 | 2011-08-09 | Medical Components, Inc. | Scrubber for medical device cleaner |
US20060030827A1 (en) * | 2004-07-14 | 2006-02-09 | Medical Components, Inc. | Luer cleaner |
US20100192975A1 (en) * | 2004-07-14 | 2010-08-05 | Medical Components, Inc. | Scrubber for Medical Device Cleaner |
EP1917057A1 (en) * | 2005-07-20 | 2008-05-07 | Manta Devices, Llc | Inhalation device |
US11491287B2 (en) | 2005-07-20 | 2022-11-08 | Manta Devices, Llc | Inhalation device |
US10632268B2 (en) | 2005-07-20 | 2020-04-28 | Manta Devices, Llc | Inhalation device |
WO2007018568A1 (en) | 2005-07-20 | 2007-02-15 | Manta Devices, Llc | Inhalation device |
EP1917057A4 (en) * | 2005-07-20 | 2017-05-03 | Manta Devices, LLC | Inhalation device |
US11672927B2 (en) | 2005-07-20 | 2023-06-13 | Manta Devices, Llc | Inhalation device |
US20100152668A1 (en) * | 2006-11-13 | 2010-06-17 | Medical Components, Inc | Method of Using a Syringe |
US8771234B2 (en) | 2006-11-13 | 2014-07-08 | Medical Components, Inc. | Syringe for sequential expression of different liquids |
US20080114304A1 (en) * | 2006-11-13 | 2008-05-15 | Medical Components, Inc | Syringe for sequential expression of different liquids and method of using same |
US8021343B2 (en) | 2006-11-13 | 2011-09-20 | Medical Components, Inc. | Syringe for sequential expression of different liquids |
US8021349B2 (en) | 2006-11-13 | 2011-09-20 | Medical Components, Inc. | Method of using a syringe |
US8771254B2 (en) | 2006-11-13 | 2014-07-08 | Medical Components, Inc. | Method of using a syringe |
US20080224336A1 (en) * | 2007-03-16 | 2008-09-18 | Vapotherm, Inc. | Water spike system |
US7654507B2 (en) * | 2007-03-16 | 2010-02-02 | Vapotherm, Inc. | Water spike system |
US11224704B2 (en) | 2007-07-06 | 2022-01-18 | Manta Devices, Llc | Dose delivery device for inhalation |
US9919115B2 (en) | 2007-07-06 | 2018-03-20 | Manta Devices, Llc | Dose delivery device for inhalation with first and second portions to open a dose chamber |
US7704002B2 (en) | 2008-02-19 | 2010-04-27 | Medical Components, Inc. | Luer cleaner with self-puncturing reservoir |
US20090205151A1 (en) * | 2008-02-19 | 2009-08-20 | Medical Components, Inc | Luer Cleaner with Self-Puncturing Reservoir |
US20150217065A1 (en) * | 2009-05-18 | 2015-08-06 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
US9474870B2 (en) * | 2009-05-18 | 2016-10-25 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
US10376662B2 (en) | 2009-05-18 | 2019-08-13 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
US20130233313A1 (en) * | 2010-11-29 | 2013-09-12 | Sanofi-Aventis Deutschland Gmbh | Medicated Module for an Inhaler |
US9427533B2 (en) * | 2010-11-29 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Medicated module for an inhaler |
US9445762B2 (en) * | 2012-08-30 | 2016-09-20 | Mystic Pharmaceuticals, Inc. | Fully self-contained unit dose devices for allergy skin testing |
US20150126898A1 (en) * | 2012-08-30 | 2015-05-07 | Mystic Pharmaceuticals, Inc. | Fully Self-Contained Unit Dose Devices for Allergy Skin Testing |
CN106163598A (en) * | 2014-04-28 | 2016-11-23 | 菲利普莫里斯生产公司 | Nicotine powder inhalator |
CN106170313A (en) * | 2014-04-28 | 2016-11-30 | 菲利普莫里斯生产公司 | Band fragrance nicotine powder inhalator |
US11878114B2 (en) | 2014-04-28 | 2024-01-23 | Philip Morris Products S.A. | Nicotine powder inhaler |
US10912334B2 (en) | 2014-04-28 | 2021-02-09 | Philip Morris Products S.A. | Flavoured nicotine powder inhaler |
US10932492B2 (en) | 2014-04-28 | 2021-03-02 | Philip Morris Products S.A. | Nicotine powder inhaler |
US11147936B2 (en) | 2014-05-02 | 2021-10-19 | Manta Devices, Llc | Dose delivery device with cover connected to dose chamber seal |
US20160101246A1 (en) * | 2014-10-10 | 2016-04-14 | Solaeromed Inc. | Apparatus and methods for producing and delivering a vapour medicament |
US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
CN109069776A (en) * | 2016-05-31 | 2018-12-21 | 菲利普莫里斯生产公司 | With the apparatus for aerosol creation for piercing through sub-assembly |
US11497251B2 (en) | 2016-05-31 | 2022-11-15 | Altria Client Services Llc | Aerosol generating device with piercing assembly |
US12268808B2 (en) | 2016-05-31 | 2025-04-08 | Altria Client Services Llc | Aerosol generating device with piercing assembly |
US11690962B2 (en) * | 2017-06-06 | 2023-07-04 | Aptar France Sas | Fluid or powdery product dispensing device |
US20200197630A1 (en) * | 2017-06-06 | 2020-06-25 | Aptar France Sas | Fluid or powdery product dispensing device |
US20210361884A1 (en) * | 2018-05-08 | 2021-11-25 | Akroswiss Ag | Bi-dose nasal spray |
US12239780B2 (en) * | 2018-05-08 | 2025-03-04 | Akroswiss Ag | Bi-dose nasal spray |
US20210393897A1 (en) * | 2018-11-19 | 2021-12-23 | Shin Nippon Biomedical Laboratories, Ltd, | Medicine dispensing device and method for manufacturing same |
EP3884980A4 (en) * | 2018-11-19 | 2022-08-17 | Shin Nippon Biomedical Laboratories, Ltd. | DRUG DELIVERY DEVICE AND METHOD OF MANUFACTURE THERE |
US12246130B2 (en) * | 2018-11-19 | 2025-03-11 | Shin Nippon Biomedical Laboratories, Ltd. | Medicine dispensing device and method for manufacturing same |
EP4114485A4 (en) * | 2020-03-05 | 2024-03-06 | Sipnose Ltd | DEVICES AND METHOD FOR DELIVERING A SUBSTANCE INTO A BODY CAVITY |
Also Published As
Publication number | Publication date |
---|---|
US20080006269A1 (en) | 2008-01-10 |
ES2229113T3 (en) | 2005-04-16 |
WO2002056950A3 (en) | 2002-10-24 |
DE60201815T2 (en) | 2005-11-24 |
WO2002056950A2 (en) | 2002-07-25 |
US6443152B1 (en) | 2002-09-03 |
DE60201815D1 (en) | 2004-12-09 |
ATE281200T1 (en) | 2004-11-15 |
EP1349598B1 (en) | 2004-11-03 |
US7270127B2 (en) | 2007-09-18 |
US20030047184A1 (en) | 2003-03-13 |
JP2004526480A (en) | 2004-09-02 |
EP1349598A2 (en) | 2003-10-08 |
JP4343530B2 (en) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6443152B1 (en) | Medicament respiratory delivery device | |
US6929005B2 (en) | Medicament respiratory delivery device, cartridge and method of making same | |
US6644309B2 (en) | Medicament respiratory delivery device and method | |
US7896836B2 (en) | Valved delivery device and method | |
US7644562B2 (en) | Method of making a cartridge for a medicament respiratory delivery device | |
US6782887B2 (en) | Medicament respiratory delivery device and cartridge | |
US7726308B1 (en) | Apparatus and method for respiratory drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BECTON DICKINSON AND COMPANY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOCKHART, ARTIS R.;SULLIVAN, VINCENT J.;MONAHAN, LAWRENCE A.;AND OTHERS;REEL/FRAME:012096/0946 Effective date: 20010713 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |